2．2．5碳酸酐抑制剂（carbonic anhydrase inhibitors）主要作用部位是近端小管，其次是远端小管， 其作用之强弱决定于血浆中HCO，浓度。
基于116个网页-相关网页
4．碳酸酐酶抑制剂（carbonic anhydrase inhibitors，CAIs）：通过减少房水的产生而降低眼压。20世纪50年代开始使用口服CAIs，局部CAIs出现以后，口服CA...
基于36个网页-相关网页
Carbonic-anhydrase inhibitors 碳酸脱水酶抑制剂类引起的有害效应
topical carbonic anhydrase inhibitors 碳酸酐酶抑制剂
Adverse effects in therapeutic use, carbonic-anhydrase inhibitors 碳酸脱水酶抑制剂的有害效应
Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides, and other diuretics 碳酸脱水酶抑制剂、苯并噻二嗪类和其他利尿剂中毒
inhibitors of carbonic anhydrase 碳酸酐酶抑制剂
Carbonic anhydrase inhibitors (CAIs) were first used to lower intraocular pressure (IOP) in glaucoma in 1954, with the introduction of acetazolamide, methazolamide and diclofenamide were subsequently.
乙酰唑胺、醋甲唑胺、双氯非那胺等碳酸酐酶抑制剂自1954年起就被应用于青光眼的降眼压治疗。
参考来源 - 醋甲唑胺脂质体滴眼剂的研究·2,447,543篇论文数据，部分数据来源于NoteExpress
Thus, systemic acidosis or the other side effects associated with oral carbonic anhydrase inhibitors are not expected to occur.
因此，不会出现全身酸中毒或其他与口服碳酸酐酶抑制剂有关的副作用。
Carbonic anhydrase inhibitors (CAIs) were first used to lower intraocular pressure (IOP) in glaucoma in 1954, with the introduction of acetazolamide, methazolamide and diclofenamide were subsequently.
乙酰唑胺、醋甲唑胺、双氯非那胺等碳酸酐酶抑制剂自1954年起就被应用于青光眼的降眼压治疗。
应用推荐